SLAMF6

Across TCGA pan-cancer cohorts, SLAMF6 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SLAMF6 data layer compared with 23 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher SLAMF6 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated SLAMF6 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

LUAD, PDAC, and LSCC are the cancer types where SLAMF6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	III,IV	0.499	0.771	.003	16	view →
PDAC	DFS	Median	II,III,IV	0.263	0.849	.038	6	view →
LSCC	DFS	Tertile	All	0.852	0.333	.012	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

SLAMF6–LUAD (OS)

Open the LUAD breakdown →